Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy.
As small bowel adenocarcinoma (SBA) is a rare cancer worldwide, prognostic factors have not been clearly defined. The purpose of this study is to assess the prognostic role of clinicopathologic features, including body mass index (BMI), in patients with advanced SBA. A total of 28 consecutive patients with advanced SBA treated with palliative chemotherapy were retrospectively enrolled and analyzed. Clinicopathologic features, progression-free survival (PFS), and overall survival (OS) were compared according to BMI level. Eighteen patients had BMI < 25 kg/m(2) (overweight/normal/underweight in Asian) and ten patients had BMI ≥ 25 kg/m(2) (obese in Asian). Baseline characteristics were similar regardless of patient's BMI. Compared to patients with BMI < 25 kg/m(2), patients with BMI ≥ 25 kg/m(2) had higher response rate to chemotherapy (40.0% vs. 0%, P = 0.010), longer OS (11.2 vs. 7.0 months, P = 0.018) and a tendency toward prolonged PFS (2.1 vs. 1.9 months, P = 0.085). Multivariate analysis revealed that BMI ≥ 25 kg/m(2) is an independent positive prognostic factor of OS (adjusted hazard ratio 0.35, P = 0.024). In conclusion, baseline BMI ≥ 25 kg/m(2) has a positive prognostic role in patients with advanced SBA.
a Department of Internal Medicine , Seoul National University Hospital , Seoul , Korea.
Dae-Won
DW
Lee
a Department of Internal Medicine , Seoul National University Hospital , Seoul , Korea.|b Cancer Research Institute , Seoul National University College of Medicine , Seoul , Korea.
Kyung-Hun
KH
Lee
a Department of Internal Medicine , Seoul National University Hospital , Seoul , Korea.|b Cancer Research Institute , Seoul National University College of Medicine , Seoul , Korea.
Tae-Yong
TY
Kim
a Department of Internal Medicine , Seoul National University Hospital , Seoul , Korea.|b Cancer Research Institute , Seoul National University College of Medicine , Seoul , Korea.
Sae-Won
SW
Han
a Department of Internal Medicine , Seoul National University Hospital , Seoul , Korea.|b Cancer Research Institute , Seoul National University College of Medicine , Seoul , Korea.
Do-Youn
DY
Oh
a Department of Internal Medicine , Seoul National University Hospital , Seoul , Korea.|b Cancer Research Institute , Seoul National University College of Medicine , Seoul , Korea.
Seock-Ah
SA
Im
a Department of Internal Medicine , Seoul National University Hospital , Seoul , Korea.|b Cancer Research Institute , Seoul National University College of Medicine , Seoul , Korea.
Tae-You
TY
Kim
a Department of Internal Medicine , Seoul National University Hospital , Seoul , Korea.|b Cancer Research Institute , Seoul National University College of Medicine , Seoul , Korea.
Yung-Jue
YJ
Bang
D000230:Adenocarcinoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D015992:Body Mass Index; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D007421:Intestine, Small / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009765:Obesity / Q000150:complications / Q000188:drug therapy; D050177:Overweight / Q000150:complications / Q000188:drug therapy; D010166:Palliative Care; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016896:Treatment Outcome